

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 761645468 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: January 10, 2006

Signature: \_\_\_\_\_

(Grace Yu)

Patent

Docket No. 140942001311



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:  
Gosse Jan ADEMA et al.

Serial No.: 10/777,524

Filing Date: February 11, 2004

For: ISOLATED MAMMALIAN  
MONOCYTE CELL GENES, RELATED  
REAGENTS

Examiner: B. Bunner

Group Art Unit: 1647

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

01/12/2006 CNGUYEN 00000001 031952 10777524

02 FC:1806 180.00 DA

sd-296544

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 140942001311.

Dated: January 10, 2006

Respectfully submitted,

By 

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON & FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-7940



ALTERNATIVE TO PTO/SB/08a/b (07-05)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/777,524
				Filing Date	February 11, 2004
				First Named Inventor	Gosse Jan ADEMA
				Art Unit	1647
				Examiner Name	B. Bunner
Sheet	1	of	1	Attorney Docket Number	140942001311

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials**	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	CLARK et al., Tissue Antigens (2001) 57:415-423	
	2.	COLONNA, Nature Reviews Immunology (2003) 3(6):445-453	
	3.	DE VET et al., The Journal of Biological Chemistry (2001) 276(45):42070-42076	
	4.	HAWKE et al., PNAS (2001) 98(24):13832-13837	
	5.	KIKUCHI-MAKI et al., The Journal of Immunology (2003) 171:3415-3425	
	6.	KUI, Cell Research (2000) 10:279-288	
	7.	LANIER in: Annual Review of Immunology, Vol. 23, Paul et al. (eds.), (2005) pp.225-274	
	8.	LEBBINK et al., The Journal of Immunology (2004) 172:5535-5543	
	9.	LEBBINK et al., Immunogenetics (2005) 57:344-351	
	10.	LOCK et al., Immunobiology (2004) 209:199-207	
	11.	LUO et al., Biochemical and Biophysical Research Communications (2001) 287:35-41	
	12.	MARSHALL et al., The Journal of Biological Chemistry (2004) 279(15):14792-14802	
	13.	MERCK et al., Immunobiology (2004) 104(5):1386-1395	
	14.	MEYAARD, Journal of Biological Regulators and Homeostatic Agents (2003) 17:330-333	
	15.	MOUSSEAU et al., The Journal of Biological Chemistry (2000) 275(6):4467-4474	
	16.	SWEENEY et al., Biochemistry (2005) 44:14932-14947	
	17.	TENCA et al., The Journal of Immunology (2005) 174:6757-6763	
	18.	TOYAMA-SORIMACHI et al., The Journal of Immunology (2005) 174:4621-4629	
	19.	TROWSDALE et al., Immunological Reviews (2001) 181:20-38	
	20.	VERBRUGGE et al., International Immunology (2003) 15(11):1349-1358	
	21.	WU et al., Gene (2003) 306:1-12	
	22.	XU et al., Biochemical and Biophysical Research Communications (2002) 293:1037-1046	
	23.	YUSA and CAMPBELL, The Journal of Immunology (2003) 170:4539-4547	
	24.	ZANNETTINO et al., Biochem. J. (2003) 370:537-549	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

sd-296542